Combination chemotherapy for metastatic breast cancer commonly achieves tumour response rates of 50-60% in large series (Aisner et al., 1987; Brambilla et al., 1976; Coates et al., 1987; Cummings et al., 1985; Tormey et al., 1982; Hayes & Henderson, 1987) but long term remissions are rare and one of the main aims of treatment is symptom palliation. It is therefore important to develop regimens that are not merely effective, but have low subjective toxicity.
Mitozantrone (Novatrone), an anthracene-dione, is an active and well tolerated new agent for metastatic breast cancer with a single agent response of 35% in a series of previously untreated patients (Stuart-Harris et al., 1984a) . Mitomycin C has likewise been shown to be active and well tolerated, with a 28% response rate even in previously treated patients (Van Oosterom et al., 1979) . Recently a combination of mitozantrone, methotrexate and mitomycin C (MMM) has been developed and shown to be as active as a vincristine, adriamycin, cyclophosphamide regimen (VAC) but less toxic (Judson et al., 1988) .
Cyclophosphamide, methotrexate and 5-FU (CMF), in a variety of schedules, remains one of the most widely used breast cancer regimens world-wide, with the majority of randomised trials suggesting similar efficacy to Adriamycin-containing regimens but usually with less toxicity (Cummings et al., 1985; Hayes & Henderson, 1987; Macaulay & Smith, 1986; Moss et al., 1978; Tormey et al., 1982) . We therefore decided to compare MMM with CMF in a randomised trial of first-line chemotherapy in patients with advanced or metastatic breast cancer. The design of the trial included cross-over treatment for non-responding or relapsed patients. Cumulative cardiotoxicity is less of a problem with mitozantrone than with structurally related Adriamycin (Benjamin et al., 1985; Henderson et al., 1989) 
Patients and methods

Patients
One hundred and twenty patients attending the breast unit at the Royal Marsden Hospital (Fulham Road), between July 1986 and March 1989 with histologically or cytologically proven breast cancer and with distant metastases or locally advanced inoperable disease were entered into this trial. Details of patient characteristics are given in Table I . The median age was 55 (range 31-72) years for CMF and 51 (range 29-80) years for MMM. Thirty-seven percent were pre-or perimenopausal (2 years since last menstrual period) for CMF and 42% for MMM (see Table I ). The majority had received at least one form of previous endocrine therapy for advanced disease (70% for CMF and 73% for MMM), but no patient had received previous chemotherapy for advanced disease or as adjuvant treatment. Eleven patients had large primary carcinomas without metastatic spread (6 CMF, 5 MMM), and 28 had metastatic disease at initial presentation (12 CMF and 16 MMM) . For the remainder the median disease-free interval was 24 months for CMF and 25 months for MMM.
Exclusion criteria were previous cytotoxic chemotherapy, significant non-metastatic cardiac, renal or hepatic disease, a life-expectancy of <3 months or unassessable disease as defined by standard UICC criteria (Hayward et al., 1977) . (Hayward et al., 1977) . Life tables were drawn using the Kaplan Meier method and comparisons were performed using the log rank test (Peto et al., 1977 Response, duration, survival No significant differences between the two groups were found for median response duration (7 months: MMM and CMF, Figure 1 ), time to progression (CMF 5 months, MMM 6 months, Figure 2 ) and overall survival (CMF 12 months, MMM 16 months, Figure 3 ). Responses by site of disease are given in Table III. Crossover responses Fifty-two patients have crossed over and 48 are evaluable for response to second line therapy. These results are shown in Table IV and have been displayed according to response to WHO Grade III or IV leucopenia (WBC <2.0 + IO' 1') occurred in 25% of patients receiving MMM and 22% of those receiving CMF. There was one death associated with leucopenia in a patient receiving CMF.
Cardiotoxicity Of the 75 patients who commenced the cardiac scan protocol only 45 (60%) had a second (post initial treatment scan). The reasons for the failure to complete these studies included poor clinical condition (27%), refusal (3%), depression (1%), chest wall radiotherapy (3%) and difficulty in travelling (7%).
Six of these 45 (13%) were noted to have a significant reduction (> 10%) in LVEF after initial treatment. Surprisingly, four of these patients had been treated with CMF. One of the two patients with reduction in LVEF whilst receiving MMM had an abnormal ECG at the start of treatment (left axis deviation) and neither patient suffered symptoms of cardiac failure. Histological examination of myocardial tissue was not undertaken.
Discussion
The combination MMM has already been reported as having a response rate and survival as good as that for vincristine, anthracycline and cyclophosphamide combination; in that trial the absence of vincristine-and anthracycline-related problems resulted in less overall toxicity (Judson et al., 1988) . This trial confirms that MMM is an active and well tolerated new chemotherapy regimen for advanced breast cancer with an efficacy, in terms of response rate and survival, and a toxicity spectrum very similar to a standard CMF regimen. It is, however at present considerably more expensive: currently in the UK a single course of MMM costs around £120 compared with £13.50 for CMF.
It must be noted that the doses of our CMF combination were lower than those reported in some other studies (Cummings et al., 1985; Aisner et al., 1987; Coates et al., 1987) , but not all: the dose rate was in fact slightly higher than the higher of two dose levels of CMF compared in a recent trial (Tannock et al., 1988) . In addition treatment actually delivered is often less than treatment planned: in a classic adjuvant CMF trial only 17% of patients received the intended dose (Bonadonna et al., 1981) . Our choice of dose was based on what we have found to be realistically achievable in clinical practice, and this was borne out by our results. Seventy-six percent of patients on CMF had some degree of neutropenia, including 22% with severe neutropenia. Sixty-eight percent had mucositis before we introduced folinic acid rescue, and 50% diarrhoea. More than one third of patients required a dose reduction or treatment delay. Such toxicity might seem relatively modest for a potentially curative regimen, but is considerable when the main aim of treatment is palliation as here. Furthermore, the response rate was in the same range as that achieved with higher dose studies.
Whilst the initial response rates are similar, a difference was seen in the crossover responses with only one patient responding to MM, having received CMF previously. However, the clinical significance of this is unclear, since numbers are small and mitozantrone has been shown to be active as a single agent in patients previously treatment with CMF (Stuart-Harris, 1984a).
Despite the low incidence of severe subjective toxicity and significant alopecia with MMM, it is nevertheless important to note that significant haematological toxicity did occur, with 43% of patients requiring treatment delay or dose reduction. This occurred despite a significant dose reduction compared with single agent studies: mitozantrone was reduced from 12-14 mgm2 (Stuart-Harris et al., 1984a) The results of our cardiotoxicity study were unexpected. Mitozantrone has established clinical cardiotoxicity (Benjamin et al., 1985; Henderson et al., 1989; Stuart-Harris et al., 1984b) although the drug appears to be significantly less clinically cardiotoxic than other anthracyclines (Henderson et al., 1989) . In the absence of predisposing factor, mitozantrone-induced cardiotoxicity is unusual at cumulative doses below 160 mg m-2 (Posner et al., 1985) , well above the cumulative dose here of 48 mg m-2 after six courses. No evidence of clinical cardiac failure was seen in this study. Four out of six patients who had significant reductions in their ventricular ejection fraction turned out to have been treated with CMF rather than MMM. This suggests that deteriorating cardiac function may relate to advanced metastatic cancer rather than directly to therapies, and casts some doubt on studies commenting on mitozantrone-and anthracycline-related cardiotoxicity using this technique alone.
There is continuing debate on what constitutes the most effective chemotherapy for metastatic breast cancer. The overall response rates and survival for both arms of this trial were similar to those reported in large series using both CMF and Adriamycin-containing regimens (Coates et al., 1987; Cummings et al., 1985; Hayes & Henderson, 1987; Macaulay & Smith, 1986; Smalley et al., 1983) . Occasionally, better results have been reported, particularly with Adriamycincontaining regimens (Aisner et al., 1987) , but these have not been confirmed by other studies. Comparisons of results between different trials are difficult because of potential variations in the selection criteria used for patient entry. In particular, as recently emphasised by Tannock et al. (1988) policies differing between Units on the timing of chemotherapy intervention in the natural history of metastatic breast cancer will influence survival from the start of treatment quite independently of therapeutic effect.
Our conclusions from our own trial and from a comparison with these other studies is that MMM now joins CMF as an effective and useful palliative treatment for metastatic breast cancer with important advantages over Adriamycincontaining regimens in terms of better patient tolerance.
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